<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Comprehensive stock analysis for Bristol-Myers Squibb Company (BMY) including financial performance, technical analysis, and investment outlook.">
    <meta name="keywords" content="BMY, Bristol-Myers Squibb Company, stock analysis, investment, financial analysis">
    <title>Bristol-Myers Squibb Company (BMY) Stock Analysis - Complete Guide</title>
    <style>
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            line-height: 1.6;
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
            color: #333;
        }
        .article-header {
            border-bottom: 3px solid #0066cc;
            padding-bottom: 20px;
            margin-bottom: 30px;
        }
        .article-header h1 {
            margin: 0 0 10px 0;
            color: #1a1a1a;
        }
        .article-meta {
            color: #666;
            font-size: 14px;
        }
        .ticker-tag {
            background: #0066cc;
            color: white;
            padding: 4px 12px;
            border-radius: 4px;
            margin-left: 15px;
        }
        h2 {
            color: #0066cc;
            margin-top: 40px;
            border-bottom: 2px solid #e0e0e0;
            padding-bottom: 10px;
        }
        h3 {
            color: #333;
            margin-top: 30px;
        }
        h4 {
            color: #555;
            margin-top: 20px;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }
        th {
            background: #0066cc;
            color: white;
            padding: 12px;
            text-align: left;
        }
        td {
            padding: 10px 12px;
            border-bottom: 1px solid #e0e0e0;
        }
        tr:hover {
            background: #f5f5f5;
        }
        ul {
            padding-left: 25px;
        }
        li {
            margin: 8px 0;
        }
        strong {
            color: #0066cc;
        }
        .faq-item {
            margin: 25px 0;
            padding: 15px;
            background: #f9f9f9;
            border-left: 4px solid #0066cc;
        }
        .faq-question {
            font-weight: bold;
            color: #1a1a1a;
            margin-bottom: 10px;
        }
        .metadata {
            margin-top: 50px;
            padding: 20px;
            background: #f0f0f0;
            border-radius: 8px;
            font-size: 12px;
            color: #666;
        }
    </style>
</head>
<body>
    
<div class="article-header">
    <h1>Bristol-Myers Squibb Company (BMY) Stock Analysis</h1>
    <div class="article-meta">
        <span class="publish-date">Published: 2025-12-04</span>
        <span class="ticker-tag">#BMY</span>
    </div>
</div>
<h2>Bristol-Myers Squibb (BMY) Stock Analysis: Navigating Pharma's Future</h2>
<p>As an expert financial journalist, I‚Äôm always looking to cut through the noise and deliver clear, actionable insights for investors. Today, we're diving deep into <a href="https://finance.yahoo.com/quote/BMY" rel="noopener" target="_blank">Bristol-Myers Squibb Company (BMY)</a>, a significant player with a <strong>$103.74 billion</strong> market cap in the dynamic Drug Manufacturers - General industry. The big question on everyone's mind is whether BMY's current stock price truly reflects its value and if the company is poised for sustainable growth. Should you consider adding this pharmaceutical giant to your portfolio right now?</p>
<p>My goal here is to provide you with a comprehensive, unbiased look at BMY. We‚Äôll explore everything from its latest technical indicators to its financial health, valuation, and what Wall Street analysts are saying. So, let‚Äôs peel back the layers and see what the data tells us about BMY's position in today's market.</p>
<h3>BMY Stock Snapshot: Key Insights for Today's Investor</h3>
<p>Here‚Äôs a quick overview of what‚Äôs happening with BMY stock right now. The shares are currently trading at <strong>$50.96</strong>, as of December 4, 2025, showing some encouraging positive momentum. Interestingly, the stock is trading comfortably above both its 50-day and 200-day moving averages, which is often a bullish sign.</p>
<p>When we look at analyst projections, the outlook seems relatively stable, with a 1-year price target of <strong>$53.05</strong>, suggesting a potential <strong>-2.8%</strong> change from today's price. However, you should note the significant annualized volatility of <strong>28.4%</strong>, which indicates that BMY‚Äôs stock can experience notable price swings. This isn't a stock for the faint of heart!</p>
<p>From a fundamental perspective, Bristol-Myers Squibb has a nuanced story. On one hand, the company boasts a robust portfolio of established pharmaceutical brands, which provides a strong foundation. On the other hand, it‚Äôs grappling with a high debt load, as evidenced by a Debt/Equity ratio of <strong>2.74x</strong>. This is definitely something to keep an eye on, especially in the current interest rate environment.</p>
<h3>What You'll Discover in This Comprehensive BMY Stock Report</h3>
<p>I believe in providing you with more than just raw numbers; I want to offer a clear, digestible analysis so you can make truly informed investment decisions. This report breaks down BMY from multiple angles:</p>
<ul>
<li><strong>Is now a good time to buy?</strong> The technical indicators suggest a "Neutral" stance, primarily because the Relative Strength Index (RSI) is signaling overbought conditions at <strong>86.1</strong>. Fundamentally, my assessment leans towards "be cautious," largely due to the company's debt levels and certain growth metrics.</li>
<li><strong>Can its core operations drive future growth?</strong> The company's future growth trajectory will heavily depend on the performance of its core Drug Manufacturers - General operations and its ability to effectively manage competitive pressures within the industry.</li>
<li><strong>What are the biggest risks?</strong> Bristol-Myers Squibb carries a substantial <strong>$51.04 billion</strong> in debt, which could become a significant headwind if interest rates continue to climb or remain elevated. Furthermore, the pharmaceutical industry is notoriously competitive, with constant innovation and new entrants challenging established players.</li>
</ul>
<p>Unlike many analyses that either drown you in jargon or offer overly simplistic "buy" recommendations, my goal is to provide you with clear, balanced information. Whether you're a long-term investor or looking for shorter-term opportunities, understanding these details is crucial. So, let's delve into the specifics and uncover what BMY truly has to offer.</p>
<h2>BMY Stock Key Metrics &amp; Latest Forecast Summary</h2>
<p>Let's kick things off with a snapshot of Bristol-Myers Squibb's most crucial metrics and what the immediate future might hold. This quick summary gives you the essential data points to understand BMY's current market standing.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Price</strong></td>
<td><strong>$50.96</strong></td>
<td>Live Market Price (as of 2025-12-04)</td>
</tr>
<tr>
<td colspan="3"><strong>Price Targets &amp; Forecasts</strong></td>
</tr>
<tr>
<td>1-Month Forecast</td>
<td>$50.96</td>
<td>üìâ -0.0%</td>
</tr>
<tr>
<td>1-Year Forecast</td>
<td>$49.54</td>
<td>üìâ -2.8%</td>
</tr>
<tr>
<td>Analyst Mean Target</td>
<td>$53.05</td>
<td>üìà +4.1% upside</td>
</tr>
<tr>
<td colspan="3"><strong>Trend &amp; Momentum</strong></td>
</tr>
<tr>
<td>Trend</td>
<td>üöÄ ‚ñ≤ Bullish</td>
<td>Price &gt; SMA 50/200</td>
</tr>
<tr>
<td>RSI (14-day)</td>
<td>86.1</td>
<td>üî• Overbought</td>
</tr>
<tr>
<td>MACD</td>
<td>üìà Bullish Short-Term Trend (0.17)</td>
<td></td>
</tr>
<tr>
<td colspan="3"><strong>Key Technical Levels</strong></td>
</tr>
<tr>
<td>Above SMA 50</td>
<td>‚úÖ $46.25</td>
<td></td>
</tr>
<tr>
<td>Above SMA 200</td>
<td>‚úÖ $46.09</td>
<td></td>
</tr>
<tr>
<td>52-Week Range</td>
<td>üìè $42.52 - $63.33</td>
<td></td>
</tr>
<tr>
<td colspan="3"><strong>Volatility</strong></td>
</tr>
<tr>
<td>Volatility (30d Ann.)</td>
<td>28.4%</td>
<td>üåä</td>
</tr>
<tr>
<td>Beta (vs. Market)</td>
<td>0.31xx</td>
<td>üõ°Ô∏è Low Sensitivity</td>
</tr>
<tr>
<td>Green Days (30d)</td>
<td>16/30 (53%)</td>
<td>üü°</td>
</tr>
<tr>
<td colspan="3"><strong>Ownership</strong></td>
</tr>
<tr>
<td>Institutional Ownership</td>
<td>81.82%</td>
<td>üèõÔ∏è</td>
</tr>
<tr>
<td>Short % of Float</td>
<td>1.56%</td>
<td>üòä Low Bearish Bets</td>
</tr>
</tbody>
</table>
<p>Currently, BMY's stock is trading at <strong>$50.96</strong>. From a technical standpoint, we're seeing a <strong>bullish pattern</strong>, as the price is comfortably holding above both its 50-day (<strong>$46.25</strong>) and 200-day (<strong>$46.09</strong>) moving averages. This suggests that the stock has been building positive momentum recently.</p>
<p>However, a word of caution: the Relative Strength Index (RSI) is at <strong>86.1</strong>, which is a strong "overbought" signal. While the MACD indicator points to a bullish short-term trend, this high RSI suggests that a minor pullback could be on the horizon before any further upward movement.</p>
<p>Over the past year, BMY's stock has traded within a range of <strong>$42.52 to $63.33</strong>. This indicates a mixed investor sentiment during that period, and the current price is sitting roughly in the middle, suggesting that extreme swings might be less likely unless a major catalyst emerges. Analysts are projecting modest growth, with a 1-year target of <strong>$49.54 (-2.8%)</strong> and an average consensus target of <strong>$53.05 (+4.1%)</strong>.</p>
<p>It's also worth noting the strong institutional backing, with <strong>81.82%</strong> institutional ownership, coupled with very low short interest at just <strong>1.56%</strong> of the float. This suggests that most large investors are betting on BMY's long-term success rather than anticipating a decline. You can find more detailed filings on the <a href="https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&amp;CIK=BMY" rel="noopener" target="_blank">SEC Edgar database</a>.</p>
<h2>BMY Price Forecast Chart &amp; Detailed Projections (2025-2026)</h2>
<p>While I can't display a live chart here, imagine a visual representation showing BMY's recent average prices alongside a forecasted price range. This "Prophet model" helps us visualize potential future movements, providing low, average, and high projections.</p>
<p>Over the forecast horizon, from December 2025 to December 2026, the model projects BMY's price to fluctuate between approximately <strong>$38.77</strong> and <strong>$59.53</strong>. It's interesting to note that the forecast uncertainty appears relatively steady, with the projected price range showing minimal change throughout this period.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Month (Period)</th>
<th>Min. Price</th>
<th>Avg. Price</th>
<th>Max. Price</th>
<th>Potential ROI vs Current ($50.96)</th>
<th>Model Signal</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025-12</td>
<td>$50.96</td>
<td>$50.96</td>
<td>$50.96</td>
<td>‚óè -0.0%</td>
<td>Hold/Neutral</td>
</tr>
<tr>
<td>2026-01</td>
<td>$47.09</td>
<td>$52.29</td>
<td>$57.48</td>
<td>‚ñ≤ 2.6%</td>
<td>Consider Buy</td>
</tr>
<tr>
<td>2026-02</td>
<td>$45.74</td>
<td>$52.06</td>
<td>$57.98</td>
<td>‚ñ≤ 2.2%</td>
<td>Hold/Neutral</td>
</tr>
<tr>
<td>2026-03</td>
<td>$43.65</td>
<td>$51.72</td>
<td>$59.53</td>
<td>‚ñ≤ 1.5%</td>
<td>Hold/Neutral</td>
</tr>
<tr>
<td>2026-04</td>
<td>$45.01</td>
<td>$51.17</td>
<td>$57.35</td>
<td>‚óè 0.4%</td>
<td>Hold/Neutral</td>
</tr>
<tr>
<td>2026-05</td>
<td>$44.36</td>
<td>$50.78</td>
<td>$57.68</td>
<td>‚óè -0.3%</td>
<td>Hold/Neutral</td>
</tr>
<tr>
<td>2026-06</td>
<td>$42.57</td>
<td>$50.07</td>
<td>$57.17</td>
<td>‚ñº -1.7%</td>
<td>Hold/Neutral</td>
</tr>
<tr>
<td>2026-07</td>
<td>$42.82</td>
<td>$50.13</td>
<td>$56.29</td>
<td>‚ñº -1.6%</td>
<td>Hold/Neutral</td>
</tr>
<tr>
<td>2026-08</td>
<td>$42.37</td>
<td>$50.36</td>
<td>$57.34</td>
<td>‚ñº -1.2%</td>
<td>Hold/Neutral</td>
</tr>
<tr>
<td>2026-09</td>
<td>$40.59</td>
<td>$49.96</td>
<td>$57.51</td>
<td>‚ñº -2.0%</td>
<td>Hold/Neutral</td>
</tr>
<tr>
<td>2026-10</td>
<td>$39.17</td>
<td>$49.23</td>
<td>$57.45</td>
<td>‚ñº -3.4%</td>
<td>Consider Short</td>
</tr>
<tr>
<td>2026-11</td>
<td>$38.77</td>
<td>$49.54</td>
<td>$58.38</td>
<td>‚ñº -2.8%</td>
<td>Consider Short</td>
</tr>
<tr>
<td>2026-12</td>
<td>$42.88</td>
<td>$50.17</td>
<td>$57.49</td>
<td>‚ñº -1.6%</td>
<td>Hold/Neutral</td>
</tr>
</tbody>
</table>
<p>Remember, these forecasts are model-based estimates and are inherently uncertain. Market conditions can change rapidly, and these projections do not guarantee future prices. Always use them as one piece of a broader analytical puzzle.</p>
<h2>Bristol-Myers Squibb Company (BMY) Profile: What They Do</h2>
<p>To truly understand a stock, you need to know the company behind it. Bristol-Myers Squibb Company is a global biopharmaceutical leader that discovers, develops, licenses, manufactures, markets, distributes, and sells a wide array of biopharmaceutical products. Their focus areas include oncology, hematology, immunology, cardiovascular, and neuroscience, among others.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sector</strong></td>
<td>Healthcare</td>
</tr>
<tr>
<td><strong>Industry</strong></td>
<td>Drug Manufacturers - General</td>
</tr>
<tr>
<td><strong>Market Cap</strong></td>
<td>103.74 B</td>
</tr>
<tr>
<td><strong>Employees</strong></td>
<td>34,100</td>
</tr>
<tr>
<td><strong>Website</strong></td>
<td><a href="https://www.bms.com" rel="noopener" target="_blank">https://www.bms.com</a></td>
</tr>
</tbody>
</table>
<h3>Business Overview</h3>
<p>Bristol-Myers Squibb's product lineup is extensive and includes several blockbuster drugs. For instance, they offer <strong>Eliquis</strong> for reducing stroke risk and treating DVT/PE, and <strong>Opdivo</strong> for various anti-cancer indications. Other significant products include <strong>Pomalyst/Imnovid</strong> for multiple myeloma, and <strong>Orencia</strong> for active rheumatoid arthritis and psoriatic arthritis.</p>
<p>Their oncology portfolio is particularly strong, featuring drugs like <strong>Sprycel</strong> for chronic myeloid leukemia, <strong>Yervoy</strong> for melanoma, and newer treatments such as <strong>Abecma</strong> for relapsed/refractory multiple myeloma and <strong>Opdualag</strong> for unresectable or metastatic melanoma. The company also offers innovative therapies like <strong>Zeposia</strong> for multiple sclerosis and <strong>Sotyktu</strong> for moderate-to-severe plaque psoriasis.</p>
<p>In addition, BMY provides <strong>Krazati</strong> for NSCLC, <strong>Camzyos</strong> for obstructive HCM, and <strong>Augtyro</strong> for ROS1-positive NSCLC. You might also recognize <strong>Revlimid</strong> for multiple myeloma and <strong>Abraxane</strong> for breast cancer, NSCLC, and pancreatic cancer. Bristol-Myers Squibb distributes its products globally to a wide range of customers, including wholesalers, distributors, pharmacies, hospitals, and government agencies.</p>
<p>Originally founded in 1887 as Bristol-Myers Company, the company is now headquartered in Princeton, New Jersey, and remains a cornerstone of the pharmaceutical industry.</p>
<h2>BMY Total Valuation: Market Cap, Enterprise Value &amp; Key Ratios</h2>
<p>Understanding a company's total valuation goes beyond just its market capitalization. While Bristol-Myers Squibb Company is recognized as a key player with a <strong>$103.74 billion</strong> market cap, its enterprise value (EV) is notably higher at <strong>$138.28 billion</strong>. This difference of <strong>$34.54 billion</strong> is primarily attributed to the company's debt load.</p>
<p>Investors often look at enterprise value to get a more complete picture of a company's total worth, as it accounts for both equity and debt. While this higher EV suggests investor confidence in BMY's future earnings, the substantial debt certainly introduces an element of risk, especially with fluctuating interest rates.</p>
<p>Let's look at the key valuation ratios:</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Market Cap</strong></td>
<td>103.74 B</td>
</tr>
<tr>
<td><strong>Enterprise Value</strong></td>
<td>138.28 B</td>
</tr>
<tr>
<td><strong>EV/Revenue (TTM)</strong></td>
<td>2.88x</td>
</tr>
<tr>
<td><strong>EV/EBITDA (TTM)</strong></td>
<td>7.20x</td>
</tr>
<tr>
<td><strong>Ex-Dividend Date</strong></td>
<td>2025-10-03</td>
</tr>
</tbody>
</table>
<p>The valuation ratios paint an interesting picture. With an EV/Revenue (TTM) of <strong>2.88x</strong> and an EV/EBITDA (TTM) of <strong>7.20x</strong>, Bristol-Myers Squibb trades at multiples that reflect its strong market position and brand assets. This suggests that the market is willing to pay a premium for its quality and established presence in the industry. However, it also implies that the stock might have less room for error, as high valuations often demand consistent performance.</p>
<p>The ex-dividend date of <strong>2025-10-03</strong> is a reminder that BMY continues to reward its shareholders, balancing growth investments with direct returns. Essentially, you're paying for a quality company, but remember that quality often comes with a higher price tag.</p>
<h2>BMY Share Statistics: Float, Ownership &amp; Short Interest Insights</h2>
<p>When you're analyzing a stock, understanding its share structure and who owns it can offer valuable insights into market dynamics and stability. For Bristol-Myers Squibb, nearly all of the company's <strong>2 billion</strong> shares are publicly available as float, meaning a significant amount isn't locked up by insiders or restricted. This high float generally allows investors to trade the stock without causing drastic price shifts.</p>
<p>However, a high float also means the company could potentially issue more shares in the future, which could dilute the value of existing stock. It‚Äôs also worth noting that executives and major shareholders own a very small portion of the company‚Äîjust <strong>0.08%</strong>. This low insider ownership might suggest that management doesn't have a substantial "skin in the game" if the company faces challenges, which is something some investors prefer to see.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Shares Outstanding</strong></td>
<td>2 B</td>
</tr>
<tr>
<td><strong>Implied Shares Outstanding</strong></td>
<td>2 B</td>
</tr>
<tr>
<td><strong>Shares Float</strong></td>
<td>2 B</td>
</tr>
<tr>
<td><strong>Insider Ownership</strong></td>
<td>0.08%</td>
</tr>
<tr>
<td><strong>Institutional Ownership</strong></td>
<td>81.82%</td>
</tr>
<tr>
<td><strong>Shares Short</strong></td>
<td>32 M</td>
</tr>
<tr>
<td><strong>Short Ratio (Days To Cover)</strong></td>
<td>2.00x</td>
</tr>
<tr>
<td><strong>Short % of Float</strong></td>
<td>1.56%</td>
</tr>
<tr>
<td><strong>Shares Short (Prior Month)</strong></td>
<td>30 M</td>
</tr>
<tr>
<td><strong>Short Date</strong></td>
<td>2025-11-14</td>
</tr>
</tbody>
</table>
<p>Conversely, the level of institutional ownership is quite significant, standing at <strong>81.82%</strong>. This substantial institutional backing often provides a degree of stability and confidence in the stock, as large funds typically conduct extensive due diligence before investing.</p>
<p>Now, let's consider the impact of short interest. With <strong>32 million</strong> shares currently shorted, representing <strong>1.56%</strong> of the float, it suggests that bearish sentiment towards BMY is relatively low. A low short interest implies that most investors aren't betting heavily against the company. While a sharp increase in short interest can signal growing doubt, the current low level, despite a slight increase from <strong>30 million</strong> last month, generally reduces the risk of a "short squeeze" and reflects a more confident market sentiment.</p>
<h2>BMY Valuation Metrics: P/E, Price/Sales &amp; EV Multiples</h2>
<p>Digging deeper into Bristol-Myers Squibb's valuation metrics provides a more granular view of how the market perceives its earnings power and asset base. The company's Trailing P/E ratio, based on past earnings, stands at <strong>17.16x</strong>. What's particularly interesting is its Forward P/E of <strong>7.25x</strong>, which suggests that analysts are anticipating attractive earnings growth ahead, making the current valuation potentially appealing.</p>
<p>Beyond earnings, we look at other multiples. BMY's Price/Sales ratio (TTM) is <strong>$2.16</strong>, and its Price/Book ratio (MRQ) is <strong>$5.59</strong>. These figures provide insight into how the market values the company relative to its revenue and book equity. They help us understand BMY's market positioning and whether it's trading at a premium or discount compared to its intrinsic value.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trailing P/E</strong></td>
<td>17.16x</td>
</tr>
<tr>
<td><strong>Forward P/E</strong></td>
<td>7.25x</td>
</tr>
<tr>
<td><strong>Price/Sales (TTM)</strong></td>
<td>$2.16</td>
</tr>
<tr>
<td><strong>Price/Book (MRQ)</strong></td>
<td>$5.59</td>
</tr>
<tr>
<td><strong>EV/Revenue (TTM)</strong></td>
<td>2.88x</td>
</tr>
<tr>
<td><strong>EV/EBITDA (TTM)</strong></td>
<td>7.20x</td>
</tr>
</tbody>
</table>
<p>From an enterprise value perspective, BMY‚Äôs EV/Revenue ratio of <strong>2.88x</strong> indicates a reasonable valuation when measured against its top-line revenue. Similarly, its EV/EBITDA multiple of <strong>7.20x</strong> suggests a fair valuation based on its earnings before interest, taxes, depreciation, and amortization. Together, these metrics offer a comprehensive view, indicating that Bristol-Myers Squibb is currently positioned with valuation multiples that warrant careful attention from investors.</p>
<h2>BMY Financial Health Check: ROE, Debt, Cash Flow &amp; Liquidity</h2>
<p>A deep dive into BMY's financial health reveals a mix of strengths and areas that warrant investor attention. The company's Return on Equity (ROE) of <strong>33.78%</strong> and Return on Assets (ROA) of <strong>9.39%</strong> are quite impressive. These high figures reflect a highly efficient use of capital, a characteristic often observed in rapidly growing firms that effectively leverage their assets to generate profits.</p>
<p>However, the <strong>2.74x</strong> Debt/Equity ratio is a significant point of consideration. With <strong>$51.04 billion</strong> in total debt against <strong>$16.50 billion</strong> in cash, BMY has clearly taken on a substantial amount of debt to fuel its operations and growth initiatives. While debt can amplify returns, it also introduces considerable financial risk, especially in a rising interest rate environment.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Return on Equity (ROE TTM)</strong></td>
<td>33.78%</td>
</tr>
<tr>
<td><strong>Return on Assets (ROA TTM)</strong></td>
<td>9.39%</td>
</tr>
<tr>
<td><strong>Debt/Equity (MRQ)</strong></td>
<td>2.74x</td>
</tr>
<tr>
<td><strong>Total Cash (MRQ)</strong></td>
<td>16.50 B</td>
</tr>
<tr>
<td><strong>Total Debt (MRQ)</strong></td>
<td>51.04 B</td>
</tr>
<tr>
<td><strong>Current Ratio (MRQ)</strong></td>
<td>1.27x</td>
</tr>
<tr>
<td><strong>Quick Ratio (MRQ)</strong></td>
<td>1.11x</td>
</tr>
<tr>
<td><strong>Operating Cash Flow (TTM)</strong></td>
<td>16.62 B</td>
</tr>
<tr>
<td><strong>Levered Free Cash Flow (TTM)</strong></td>
<td>14.72 B</td>
</tr>
</tbody>
</table>
<p>Despite this high debt, BMY's ability to generate <strong>$16.62 billion</strong> in operating cash flow (TTM) is a significant strength. This demonstrates that its core business can consistently produce substantial cash, which is crucial for servicing debt and funding operations. Furthermore, the company maintains a solid liquidity position, indicated by a Current Ratio of <strong>1.27x</strong> and a Quick Ratio of <strong>1.11x</strong>, suggesting it can cover its short-term liabilities effectively.</p>
<p>The <strong>$14.72 billion</strong> in levered free cash flow further reinforces its financial resilience, showing that BMY can still generate considerable cash for shareholders even after meeting its financial obligations. Overall, while the debt load is high, strong cash flow generation and adequate liquidity help to mitigate some of that risk.</p>
<h2>BMY Financial Efficiency: Asset Turnover, Inventory &amp; Cash Conversion</h2>
<p>When evaluating a company, it's essential to look at how efficiently it manages its assets and converts them into sales and cash. Bristol-Myers Squibb's Asset Turnover of <strong>0.52x</strong> suggests that it generates approximately <strong>$0.52</strong> in revenue for every dollar of assets it holds. This indicates a moderate level of efficiency in utilizing its asset base.</p>
<p>Breaking down further, the Inventory Turnover of <strong>5.46x</strong> means that Bristol-Myers Squibb sells and replaces its inventory about 5.5 times annually. This translates to roughly <strong>66.8</strong> Days Inventory Outstanding, which is a key metric for understanding how quickly products move off the shelves.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Asset Turnover (TTM)</strong></td>
<td>0.52x</td>
</tr>
<tr>
<td><strong>Inventory Turnover (TTM)</strong></td>
<td>5.46x</td>
</tr>
<tr>
<td><strong>Receivables Turnover (TTM)</strong></td>
<td>5.33x</td>
</tr>
<tr>
<td><strong>Working Capital Turnover (TTM)</strong></td>
<td>8.00x</td>
</tr>
<tr>
<td><strong>Current Ratio (MRQ)</strong></td>
<td>1.27x</td>
</tr>
<tr>
<td><strong>Days Sales Outstanding</strong></td>
<td>68.5</td>
</tr>
<tr>
<td><strong>Days Inventory Outstanding</strong></td>
<td>66.8</td>
</tr>
<tr>
<td><strong>Cash Conversion Cycle</strong></td>
<td>~135.3 days (partial)</td>
</tr>
<tr>
<td><strong>Return on Invested Capital (ROIC TTM)</strong></td>
<td>9.15%</td>
</tr>
</tbody>
</table>
<p>Meanwhile, the Receivables Turnover of <strong>5.33x</strong> and <strong>68.5</strong> Days Sales Outstanding reflect somewhat slower collections from customers, an area that management might need to monitor. In contrast, the Working Capital Turnover of <strong>8.00x</strong> points to a highly efficient use of short-term assets to support sales, which is a positive sign. This is further supported by the Current Ratio of <strong>1.27x</strong>, signaling adequate short-term liquidity.</p>
<p>The Cash Conversion Cycle, estimated at approximately <strong>135.3 days (partial)</strong>, suggests that it takes BMY roughly 4.5 months to convert its inventory and receivables into cash. This extended cycle could potentially strain working capital and is an area for investors to watch. Finally, a Return on Invested Capital (ROIC) of <strong>9.15%</strong> indicates moderate capital efficiency, showing how effectively the company generates returns from its invested capital. To boost profitability further, BMY may need to achieve higher asset utilization. Comparing these figures to industry peers will provide a clearer picture of its competitive standing.</p>
<h2>BMY Profitability &amp; Growth: Margins, Revenue &amp; Earnings Power</h2>
<p>When assessing a pharmaceutical giant like Bristol-Myers Squibb, profitability and growth are paramount. My analysis of BMY's margin performance reveals a company with solid control over its costs and pricing strategies. A gross margin of <strong>73.15%</strong> clearly demonstrates its success in managing production costs, which is highly impressive for a drug manufacturer.</p>
<p>Furthermore, BMY profits well from its core operations, reflected in a robust <strong>31.57%</strong> operating margin. The <strong>40.01%</strong> EBITDA margin is particularly strong, indicating BMY‚Äôs capability to generate significant cash flow from its operations before considering financing and tax strategies. All things considered, BMY manages to retain about <strong>$12.570</strong> in net profit for every dollar of revenue over the last twelve months.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profit Margin (TTM)</strong></td>
<td>12.57%</td>
</tr>
<tr>
<td><strong>Operating Margin (TTM)</strong></td>
<td>31.57%</td>
</tr>
<tr>
<td><strong>Gross Margin (TTM)</strong></td>
<td>73.15%</td>
</tr>
<tr>
<td><strong>EBITDA Margin (TTM)</strong></td>
<td>40.01%</td>
</tr>
<tr>
<td><strong>Revenue (TTM)</strong></td>
<td>48.03 B</td>
</tr>
<tr>
<td><strong>Quarterly Revenue Growth (YoY)</strong></td>
<td>2.80%</td>
</tr>
<tr>
<td><strong>Gross Profit (TTM)</strong></td>
<td>35.14 B</td>
</tr>
<tr>
<td><strong>EBITDA (TTM)</strong></td>
<td>19.22 B</td>
</tr>
<tr>
<td><strong>Net Income (TTM)</strong></td>
<td>6.04 B</td>
</tr>
<tr>
<td><strong>Earnings Growth (YoY)</strong></td>
<td>80.90%</td>
</tr>
</tbody>
</table>
<p>While the business's revenue is increasing at a respectable rate of <strong>2.80%</strong> year-over-year, investors should closely monitor whether this pace can be sustained without eroding those healthy profit margins. BMY's <strong>$19.22 billion</strong> in EBITDA and <strong>$35.14 billion</strong> in gross profit highlight its raw earning power. The <strong>$6.04 billion</strong> in net income then shows how effectively this power translates into bottom-line results.</p>
<p>It appears BMY is striking a good balance between pursuing growth and maintaining profitability. However, there's a noticeable gap between the company's gross and net margins (<strong>73.15%</strong> vs. <strong>12.57%</strong>). This suggests significant operating expenses, interest costs, or taxes are at play, which are crucial areas for investors to monitor. Moving forward, defending its pricing power and controlling operating costs will be critical for BMY to sustain profitability, especially if revenue growth slows down.</p>
<h2>BMY Dividend Analysis: Yield, Payout Ratio &amp; Shareholder Returns</h2>
<p>For income-focused investors, Bristol-Myers Squibb‚Äôs dividend profile is certainly worth a close look. The company currently offers a substantial <strong>$2.48 annual dividend per share</strong>, which translates into an attractive dividend yield of <strong>4.87%</strong>. This means that for every <strong>$100</strong> invested, shareholders can expect to receive <strong>$2.48</strong> in dividends annually.</p>
<p>What makes this even more compelling for current investors is that the present yield is <strong>above its 5-year average of 3.83%</strong>. This makes BMY stock comparatively more appealing to income seekers today than it has been in recent history.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dividend Rate</strong></td>
<td>$2.48</td>
</tr>
<tr>
<td><strong>Dividend Yield</strong></td>
<td>4.87%</td>
</tr>
<tr>
<td><strong>Payout Ratio</strong></td>
<td>83.50%</td>
</tr>
<tr>
<td><strong>5 Year Average Dividend Yield</strong></td>
<td>3.83%</td>
</tr>
<tr>
<td><strong>Trailing Dividend Rate</strong></td>
<td>$2.48</td>
</tr>
<tr>
<td><strong>Trailing Dividend Yield</strong></td>
<td>0.05%</td>
</tr>
<tr>
<td><strong>Ex-Dividend Date</strong></td>
<td>2025-10-03</td>
</tr>
<tr>
<td><strong>Last Split Date</strong></td>
<td>2001-08-07</td>
</tr>
<tr>
<td><strong>Last Split Factor</strong></td>
<td>1000000:951777</td>
</tr>
</tbody>
</table>
<h3>Key Observations &amp; Analysis:</h3>
<ul>
<li>The <strong>payout ratio of 83.50%</strong> is relatively high. While it indicates that the company uses about 84% of its earnings to fund dividends, leaving some room for reinvestment or future increases, investors should still monitor cash flow sustainability.</li>
<li>The very low <strong>trailing yield of 0.05%</strong> might initially seem confusing. This often hints at a very recent dividend initiation or perhaps a special, non-recurring payout in the past, warranting further investigation into the consistency of its dividend history.</li>
<li>For those looking to capture the next dividend, you must own the stock before the upcoming <strong>ex-dividend date of 2025-10-03</strong>.</li>
<li>The last stock split (1000000:951777 in 2001) is quite old and likely irrelevant to BMY's current valuation or investment thesis.</li>
</ul>
<h3>Investor Takeaway:</h3>
<ul>
<li><strong>Income Investors:</strong> The dividend appears sustainable given the payout ratio, but it's always wise to monitor earnings and cash flow closely to ensure the payout remains well-supported.</li>
<li><strong>Growth Investors:</strong> BMY strikes a balance between returning capital to shareholders and reinvesting for future growth, making it an appealing option for a 'growth and income' strategy.</li>
<li><strong>Watch For:</strong> Keep an eye out for announcements of dividend hikes, which could push the yield closer to its historical average, or significant stock price movements that would naturally alter the yield.</li>
</ul>
<h2>BMY Technical Analysis: Price Trends, Momentum &amp; Key Levels</h2>
<p>Let's shift gears and look at what the charts are telling us about Bristol-Myers Squibb (BMY) stock. Currently, BMY is trading at <strong>$50.96</strong>. The overall trend remains <strong>BULLISH</strong>, but there are some signs suggesting it might be getting a little overheated in the short term.</p>
<p>The stock has had a notable run recently, gaining <strong>+8.29% in just 15 days</strong>. While this momentum is impressive, several technical indicators suggest caution. It's crucial for us to break down these signals to understand how to position ourselves effectively.</p>
<h3>Trend Strength ‚Äì Still Bullish</h3>
<p>BMY is trading above its key moving averages, which is a classic confirmation of an intact uptrend. Specifically, the <strong>20-day Simple Moving Average (SMA) at $47.78</strong> is currently acting as immediate dynamic support. As long as BMY holds above this level, the bullish momentum could very well continue.</p>
<p>However, keep in mind that a rapid rise can push a stock far above its averages, which naturally increases the risk of a sharp pullback to revert to the mean.</p>
<h3>Momentum Check ‚Äì Time to Be Cautious</h3>
<p>This is where we see some yellow flags. The <strong>Relative Strength Index (RSI) at 86.1</strong> is flashing a strong overbought signal. Historically, when the RSI climbs above 70-75, it often precedes a pullback or consolidation before the next leg higher. At the same time, the MACD histogram remains positive, confirming that the underlying upward momentum is still present, albeit potentially stretched.</p>
<p>For traders, an aggressive approach might involve taking partial profits now. More conservative traders might want to wait for the RSI to cool down below 70 before considering new positions.</p>
<h3>Bollinger Bands ‚Äì Testing Key Levels</h3>
<p>The price action shows BMY "walking the band," trading <strong>above the upper Bollinger Band ($50.82)</strong>. This is typically a sign of a very strong trend, indicating significant buying pressure. However, it also means the stock is extended, and there's an increased risk of a sharp snap-back towards the middle band if momentum begins to stall.</p>
<h3>Key Levels to Watch:</h3>
<ul>
<li><strong>Resistance:</strong> Keep an eye on <strong>$51.34</strong>, which is the recent high. A confirmed breakout above this level, ideally with strong volume, could propel BMY even higher.</li>
<li><strong>Support:</strong> The immediate support level is the <strong>20-day SMA at $47.78</strong>. If this breaks, we should expect a test of <strong>$44.74</strong>.</li>
</ul>
<h3>Volume Trends ‚Äì Checking for Conviction</h3>
<p>Current trading volume is near its recent average. This provides neutral confirmation of the current price action. Ideally, we'd like to see increasing volume on upward moves and decreasing volume on downward moves to confirm strong conviction.</p>
<h3>Support &amp; Resistance ‚Äì The Trading Plan</h3>
<p>Here's a simplified trading plan based on these technical observations:</p>
<ul>
<li>‚úÖ <strong>If BMY holds above $47.78:</strong> The bullish trend is likely to continue, with the next target potentially being <strong>$51.34</strong>.</li>
<li>‚ö†Ô∏è <strong>If it breaks below $47.78:</strong> Expect a dip towards <strong>$44.74</strong>, which could be a temporary consolidation.</li>
<li>üõë <strong>A drop below $44.74:</strong> This could signal a deeper correction, potentially towards the 200-day SMA (<strong>$46.09</strong>), offering a more significant buying opportunity for long-term investors.</li>
</ul>
<h3>Final Verdict ‚Äì Should You Buy, Hold, or Sell?</h3>
<ul>
<li><strong>Short-Term Traders:</strong> Be cautious. The RSI is overbought at <strong>86.1</strong>, and volume isn't exceptionally strong. Consider locking in partial profits near <strong>$51.34</strong> and waiting for a better entry point closer to the 20-day SMA (<strong>$47.78</strong>).</li>
<li><strong>Long-Term Investors:</strong> The long-term uptrend for BMY remains valid as long as the price stays above the 200-day SMA (<strong>$46.09</strong>). A pullback to the 50-day SMA (<strong>$46.25</strong>) area could present a safer and more attractive buying opportunity.</li>
<li><strong>New Buyers:</strong> Avoid chasing this current rally. It's prudent to wait for either a confirmed breakout above <strong>$51.34</strong> with strong volume or a healthy pullback to the <strong>$47.78</strong> area, which would offer a much better risk/reward entry.</li>
</ul>
<p><strong>Bottom Line:</strong> The technical indicators suggest that BMY's rally may be running out of steam in the very short term. While the long-term trend appears bullish, a correction seems plausible before the next significant move. Trade carefully and await confirmation at key technical levels.</p>
<h3>BMY Technical Chart Overviews: Visualizing Price Action</h3>
<p>While I can't embed live charts here, understanding what they depict is crucial for technical analysis. Imagine looking at detailed charts for Bollinger Bands, RSI, MACD, and historical price and volume. These visuals would reinforce the points discussed in the technical analysis section.</p>
<ul>
<li><strong>Bollinger Bands Chart:</strong> This chart would visually confirm the price currently trading above the upper band, indicating strong momentum but also potential for a reversion.</li>
<li><strong>RSI Chart:</strong> You'd see the RSI line clearly in the overbought territory (above 70), reinforcing the caution advised for short-term traders.</li>
<li><strong>MACD Charts:</strong> These would show the MACD line above the signal line, with a positive histogram, confirming the bullish short-term momentum, but perhaps showing signs of slowing strength.</li>
<li><strong>Historical Price &amp; Volume Chart:</strong> This chart would display BMY's closing prices and trading volume over time, highlighting the recent 15-day surge and allowing you to compare current volume to its 20-day average, as mentioned in our analysis.</li>
</ul>
<p>These charts are indispensable tools for any investor looking to make informed decisions based on price action and market momentum.</p>
<h2>BMY Historical Performance &amp; Recent Trading Data</h2>
<p>Let's take a closer look at Bristol-Myers Squibb's recent stock performance to understand its trajectory. In the trading period from November 19, 2025, to December 03, 2025, BMY's stock price delivered a total return of an impressive <strong>+11.29%</strong>. During this time, the price experienced fluctuations, reaching a high of <strong>$51.34</strong> and dipping to a low of <strong>$45.27</strong>. The average daily trading volume during this period was approximately <strong>13,771,307</strong> shares, indicating decent liquidity.</p>
<h3>Recent Trading Data</h3>
<table class="financial-data-table">
<thead>
<tr>
<th>Date</th>
<th>Open</th>
<th>High</th>
<th>Low</th>
<th>Close</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025-12-03</td>
<td>$49.94</td>
<td>$51.34</td>
<td>$49.43</td>
<td>$50.96</td>
<td>27,115,800</td>
</tr>
<tr>
<td>2025-12-02</td>
<td>$48.95</td>
<td>$49.18</td>
<td>$48.22</td>
<td>$48.25</td>
<td>14,475,700</td>
</tr>
<tr>
<td>2025-12-01</td>
<td>$49.23</td>
<td>$49.86</td>
<td>$48.76</td>
<td>$49.18</td>
<td>11,772,900</td>
</tr>
<tr>
<td>2025-11-30</td>
<td>$49.23</td>
<td>$49.37</td>
<td>$49.01</td>
<td>$49.20</td>
<td>6,187,100</td>
</tr>
<tr>
<td>2025-11-29</td>
<td>$49.23</td>
<td>$49.37</td>
<td>$49.01</td>
<td>$49.20</td>
<td>6,187,100</td>
</tr>
<tr>
<td>2025-11-28</td>
<td>$49.23</td>
<td>$49.37</td>
<td>$49.01</td>
<td>$49.20</td>
<td>6,187,100</td>
</tr>
<tr>
<td>2025-11-27</td>
<td>$49.02</td>
<td>$49.50</td>
<td>$48.80</td>
<td>$49.25</td>
<td>11,373,500</td>
</tr>
<tr>
<td>2025-11-26</td>
<td>$49.02</td>
<td>$49.50</td>
<td>$48.80</td>
<td>$49.25</td>
<td>11,373,500</td>
</tr>
<tr>
<td>2025-11-25</td>
<td>$48.21</td>
<td>$49.40</td>
<td>$48.10</td>
<td>$49.05</td>
<td>15,000,000</td>
</tr>
<tr>
<td>2025-11-24</td>
<td>$48.19</td>
<td>$48.63</td>
<td>$47.58</td>
<td>$47.76</td>
<td>27,383,800</td>
</tr>
<tr>
<td>2025-11-23</td>
<td>$46.17</td>
<td>$46.99</td>
<td>$45.52</td>
<td>$46.25</td>
<td>14,183,500</td>
</tr>
<tr>
<td>2025-11-22</td>
<td>$46.17</td>
<td>$46.99</td>
<td>$45.52</td>
<td>$46.25</td>
<td>14,183,500</td>
</tr>
<tr>
<td>2025-11-21</td>
<td>$46.17</td>
<td>$46.99</td>
<td>$45.52</td>
<td>$46.25</td>
<td>14,183,500</td>
</tr>
<tr>
<td>2025-11-20</td>
<td>$45.90</td>
<td>$46.20</td>
<td>$45.27</td>
<td>$45.94</td>
<td>12,137,600</td>
</tr>
<tr>
<td>2025-11-19</td>
<td>$47.00</td>
<td>$47.00</td>
<td>$45.74</td>
<td>$45.79</td>
<td>14,825,000</td>
</tr>
</tbody>
</table>
<h2>BMY Stock Price Statistics: Volatility &amp; Moving Averages</h2>
<p>Looking at BMY's stock price statistics gives us a better context for its current trading range and how it behaves relative to the broader market. Over the past year, the stock has seen a high of <strong>$63.33</strong> and a low of <strong>$42.52</strong>. This moderate range indicates that BMY has experienced notable price swings, offering both opportunities and risks for investors.</p>
<p>Interestingly, the narrative states that the 50-day moving average at <strong>$46.25</strong> is slightly above the 200-day moving average of <strong>$46.09</strong>. This configuration is often referred to as a 'golden cross,' which is typically considered a bullish signal, suggesting positive long-term momentum. However, it's worth noting that the table below, which provides overall stock price statistics, shows slightly different moving average values for the 50-day and 200-day MAs, reflecting potentially different calculation periods or real-time updates.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>52 Week High</strong></td>
<td>$63.33</td>
</tr>
<tr>
<td><strong>52 Week Low</strong></td>
<td>$42.52</td>
</tr>
<tr>
<td><strong>50 Day MA</strong></td>
<td>$45.65</td>
</tr>
<tr>
<td><strong>200 Day MA</strong></td>
<td>$49.13</td>
</tr>
<tr>
<td><strong>Beta</strong></td>
<td>0.31x</td>
</tr>
<tr>
<td><strong>Volatility (30d Ann.)</strong></td>
<td>28.4%</td>
</tr>
</tbody>
</table>
<p>With a Beta of <strong>0.31x</strong>, BMY tends to be less volatile than the broader market, moving about 69% less than the overall market. This low Beta suggests it could be a relatively stable component in a diversified portfolio. Combined with a moderate 30-day annualized volatility of <strong>28.4%</strong>, it's clear that while BMY experiences frequent price swings, they are generally less exaggerated than those of high-beta stocks.</p>
<p>For investors, this combination suggests potential for gains without the extreme rollercoaster ride of highly volatile assets. These indicators are crucial when you're deciding on position sizing or the optimal timing for entry, especially if you're aiming to balance stability with growth exposure in your investment strategy.</p>
<h2>BMY Quarterly Earnings Performance &amp; Growth Metrics</h2>
<p>Examining Bristol-Myers Squibb‚Äôs recent quarterly performance offers vital clues into its operational health and growth trajectory. In its latest reported quarter (2025-Q3), BMY posted revenue of <strong>$12.22 billion</strong> and a net income of <strong>$2.20 billion</strong>. These figures represent the company‚Äôs ability to generate sales and convert them into profit.</p>
<p>Looking at growth trends, the quarter-over-quarter revenue change was a slight decrease of <strong>-0.4%</strong>. However, the year-over-year revenue growth stands at a positive <strong>+2.8%</strong>, indicating a modest expansion over a longer period. This suggests that while there might be some short-term fluctuations, the company is still growing on an annual basis.</p>
<h3>Recent Quarterly Results (Last 4 Quarters)</h3>
<table class="financial-data-table">
<thead>
<tr>
<th>Quarter</th>
<th>Revenue</th>
<th>Net Income</th>
<th>EPS</th>
<th>Gross Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025-Q3</td>
<td>12.22 B</td>
<td>2.20 B</td>
<td>1.08x</td>
<td>71.9%</td>
</tr>
<tr>
<td>2025-Q2</td>
<td>12.27 B</td>
<td>1.31 B</td>
<td>0.64x</td>
<td>72.5%</td>
</tr>
<tr>
<td>2025-Q1</td>
<td>11.20 B</td>
<td>2.46 B</td>
<td>1.20x</td>
<td>72.9%</td>
</tr>
<tr>
<td>2024-Q4</td>
<td>12.34 B</td>
<td>72.00 M</td>
<td>0.04x</td>
<td>61.0%</td>
</tr>
</tbody>
</table>
<h3>Growth Metrics</h3>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>QoQ Revenue Growth</strong></td>
<td>-0.4%</td>
</tr>
<tr>
<td><strong>QoQ Net Income Growth</strong></td>
<td>+68.0%</td>
</tr>
<tr>
<td><strong>YoY Revenue Growth</strong></td>
<td>+2.8%</td>
</tr>
</tbody>
</table>
<p>What really stands out is the significant quarter-over-quarter net income growth of <strong>+68.0%</strong>. This dramatic increase suggests that BMY has made considerable strides in improving its profitability in the most recent quarter, even with a slight dip in revenue. This could be due to cost efficiencies, strategic product launches, or other operational improvements. Investors should look into the specifics of these quarterly reports for more details.</p>
<h2>BMY Short Selling Insights: Shares Short &amp; Bearish Sentiment</h2>
<p>Understanding the short selling activity surrounding a stock can give you a window into bearish sentiment and potential market dynamics. For Bristol-Myers Squibb (BMY), there's currently <strong>32 million</strong> shares worth of short interest. The short ratio, or "days to cover," stands at <strong>2.0x</strong>. This means that, at BMY's recent average trading volume, it would take approximately 2 days for all existing short positions to be covered.</p>
<p>This low short ratio suggests that short sellers do not currently wield significant control over BMY's stock price. A short ratio this low often implies that the risk of a prolonged "short squeeze"‚Äîa rapid price increase caused by short sellers buying back shares‚Äîis relatively low. Investors generally perceive this as a sign of underlying stability.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Shares Short</strong></td>
<td>32 M</td>
</tr>
<tr>
<td><strong>Short Ratio (Days To Cover)</strong></td>
<td>2.00x</td>
</tr>
<tr>
<td><strong>Short % of Float</strong></td>
<td>1.56%</td>
</tr>
<tr>
<td><strong>Shares Short (Prior Month)</strong></td>
<td>30 M</td>
</tr>
<tr>
<td><strong>Short Date</strong></td>
<td>2025-11-14</td>
</tr>
</tbody>
</table>
<p>With only <strong>1.56%</strong> of the public float sold short, a very low percentage of available shares are being bet against. This indicates a general lack of strong bearish sentiment among investors, suggesting that most market participants are either neutral or positive on BMY's prospects. While this level has seen a slight increase from <strong>30 million</strong> shares shorted in the prior month, it's still considered quite low overall.</p>
<p>When short interest is low, the market tends to feel more confident about the stock. This also reduces the risks of sudden, sharp price swings that can occur due to short-covering activities, contributing to a more predictable trading environment for BMY.</p>
<h2>BMY Risk Analysis: Volatility, VaR &amp; Drawdown Potential</h2>
<p>Every investment comes with a degree of risk, and understanding Bristol-Myers Squibb's risk profile is crucial for making informed decisions. BMY exhibits moderate volatility, with an annualized volatility of <strong>20.9%</strong>. This figure indicates a moderate level of investment risk, meaning the stock can experience notable price movements, but typically not to the extremes of highly volatile assets.</p>
<p>The Sharpe ratio of <strong>0.02x</strong> suggests mixed risk-adjusted returns. A low Sharpe ratio indicates that the returns generated by the stock may not adequately compensate for the level of risk taken. This is an important metric for investors who prioritize efficiency in their risk-taking.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Volatility (Annualized)</strong></td>
<td>20.9%</td>
</tr>
<tr>
<td><strong>Value at Risk (5%)</strong></td>
<td>-1.89%</td>
</tr>
<tr>
<td><strong>Value at Risk (1%)</strong></td>
<td>-3.88%</td>
</tr>
<tr>
<td><strong>Sharpe Ratio</strong></td>
<td>0.02x</td>
</tr>
<tr>
<td><strong>Sortino Ratio</strong></td>
<td>0.02x</td>
</tr>
<tr>
<td><strong>Maximum Drawdown</strong></td>
<td>-47.67%</td>
</tr>
<tr>
<td><strong>Skewness</strong></td>
<td>-1.02x</td>
</tr>
<tr>
<td><strong>Kurtosis</strong></td>
<td>18.15x</td>
</tr>
</tbody>
</table>
<p>A significant data point is the maximum drawdown of <strong>-47.67%</strong>. This indicates that, at its worst, BMY's stock price has fallen by nearly half from its peak during adverse market conditions. This highlights a substantial downside risk that investors must be prepared for.</p>
<p>To further quantify potential losses, the Value at Risk (VaR) at a 5% confidence level shows a potential loss of <strong>-1.89%</strong> in the worst 5% of scenarios. At a stricter 1% confidence level, the potential loss increases to <strong>-3.88%</strong>. The Sortino ratio, also at <strong>0.02x</strong>, focuses specifically on downside risk and provides additional insight into risk-adjusted performance by penalizing only negative volatility.</p>
<p>Finally, the Skewness of <strong>-1.02x</strong> suggests that BMY's returns distribution has a long tail on the negative side, implying a higher probability of large negative returns than large positive returns. The high Kurtosis of <strong>18.15x</strong> indicates that extreme returns (both positive and negative) are more likely than in a normal distribution. Investors should carefully consider all these risk metrics in conjunction with their own risk tolerance and investment objectives before making any decisions.</p>
<h2>BMY Sentiment Analysis: Market Mood &amp; Options Activity</h2>
<p>Understanding the prevailing market sentiment for a stock like Bristol-Myers Squibb (BMY) can provide a valuable, albeit often subjective, layer to your analysis. Our current market sentiment analysis for BMY reveals a cautiously positive outlook, with a composite sentiment score of <strong>0.18x</strong> and a confidence level of <strong>36.6%</strong>. This positive sentiment is drawn from a variety of data sources, including recent news coverage, analyst recommendations, and activity in the options market.</p>
<p>Let's break down the individual components of this sentiment:</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Composite Sentiment Score</strong></td>
<td>0.18x</td>
</tr>
<tr>
<td><strong>Sentiment Classification</strong></td>
<td>Positive</td>
</tr>
<tr>
<td><strong>Sentiment Confidence</strong></td>
<td>36.6%</td>
</tr>
<tr>
<td><strong>News Sentiment</strong></td>
<td>Neutral (-0.01x)</td>
</tr>
<tr>
<td><strong>Analyst Sentiment</strong></td>
<td>Neutral (0.00x)</td>
</tr>
<tr>
<td><strong>Options Sentiment</strong></td>
<td>Positive (0.56x)</td>
</tr>
<tr>
<td><strong>Put/Call Ratio</strong></td>
<td>0.22x</td>
</tr>
</tbody>
</table>
<p>Drilling down, news analysis shows a largely Neutral sentiment at <strong>-0.01x</strong>, indicating that recent headlines haven't significantly swayed the overall mood one way or another. Similarly, the analyst consensus registers as Neutral with a score of <strong>0.00x</strong>, implying a balanced view among Wall Street experts. However, the options market sentiment stands out as distinctly Positive, with a score of <strong>0.56x</strong>. This suggests that options traders might be anticipating upward movement for BMY, perhaps through a higher volume of call options compared to puts, as indicated by a Put/Call Ratio of <strong>0.22x</strong>.</p>
<p>It's important to remember that this is a relatively weak sentiment signal due to the moderate confidence level. Therefore, this sentiment data should always be considered alongside a thorough fundamental and technical analysis to form a comprehensive investment perspective. No single indicator tells the whole story.</p>
<h2>BMY Peer Comparison: How Bristol-Myers Squibb Stacks Up</h2>
<p>To truly understand Bristol-Myers Squibb's position, it's essential to compare it against its industry peers. Let's stack BMY against some other major players in the pharmaceutical sector: Eli Lilly and Company (LLY), Johnson &amp; Johnson (JNJ), and Merck &amp; Co., Inc. (MRK). This comparison highlights BMY's relative strengths and weaknesses across key financial metrics.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>BMY</th>
<th>LLY</th>
<th>JNJ</th>
<th>MRK</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Market Cap</strong></td>
<td>$103.74B</td>
<td>$926.54B</td>
<td>$494.70B</td>
<td>$255.45B</td>
</tr>
<tr>
<td><strong>P/E Ratio</strong></td>
<td>17.16</td>
<td>50.76</td>
<td>19.84</td>
<td>13.53</td>
</tr>
<tr>
<td><strong>Revenue Growth</strong></td>
<td>2.80%</td>
<td>53.90%</td>
<td>6.80%</td>
<td>3.70%</td>
</tr>
<tr>
<td><strong>Net Margin</strong></td>
<td>12.57%</td>
<td>30.99%</td>
<td>27.26%</td>
<td>29.63%</td>
</tr>
<tr>
<td><strong>EPS</strong></td>
<td>2.97</td>
<td>20.36</td>
<td>10.35</td>
<td>7.56</td>
</tr>
<tr>
<td><strong>ROE</strong></td>
<td>33.78%</td>
<td>96.47%</td>
<td>33.62%</td>
<td>39.49%</td>
</tr>
<tr>
<td><strong>Debt-to-Equity</strong></td>
<td>274</td>
<td>179</td>
<td>57.77</td>
<td>79.71</td>
</tr>
<tr>
<td><strong>Dividend Yield</strong></td>
<td>4.87%</td>
<td>58.00%</td>
<td>2.53%</td>
<td>3.32%</td>
</tr>
<tr>
<td><strong>52-Week Range</strong></td>
<td>42.38 - 61.00</td>
<td>621.50 - 1111.99</td>
<td>136.50 - 207.81</td>
<td>71.87 - 105.84</td>
</tr>
</tbody>
</table>
<p>Bristol-Myers Squibb, with its <strong>$103.74 billion</strong> market cap, stands as the smallest among these pharmaceutical giants, dwarfed by LLY (<strong>$926.54 billion</strong>), JNJ (<strong>$494.70 billion</strong>), and MRK (<strong>$255.45 billion</strong>). BMY's P/E ratio of <strong>17.16</strong> suggests a value-oriented pricing compared to LLY‚Äôs premium multiple of <strong>50.76</strong>. JNJ (<strong>19.84</strong>) and MRK (<strong>13.53</strong>) trade at lower multiples, often reflecting more mature or slower-growth business models.</p>
<p>In terms of revenue growth, BMY shows a modest <strong>2.80%</strong> expansion, which pales in comparison to LLY‚Äôs impressive <strong>53.90%</strong>, indicating a much stronger recent growth momentum for Eli Lilly. BMY‚Äôs net margin of <strong>12.57%</strong>, while positive, is considerably lower than LLY (<strong>30.99%</strong>), JNJ (<strong>27.26%</strong>), and MRK (<strong>29.63%</strong>), highlighting differences in profitability efficiency.</p>
<p>However, BMY shines with an exceptional Return on Equity (ROE) of <strong>33.78%</strong>, signaling highly efficient use of shareholder equity, comparable to JNJ‚Äôs <strong>33.62%</strong> and MRK‚Äôs <strong>39.49%</strong>, though LLY's ROE is an outlier at <strong>96.47%</strong>. On the debt front, BMY‚Äôs high Debt-to-Equity ratio of <strong>274</strong> indicates significant financial leverage, even higher than LLY‚Äôs <strong>179</strong>, and notably higher than JNJ‚Äôs <strong>57.77</strong> and MRK‚Äôs <strong>79.71</strong>.</p>
<p>Finally, BMY offers a compelling <strong>4.87%</strong> dividend yield to shareholders, which is attractive, though LLY's reported dividend yield of <strong>58.00%</strong> is an anomaly that would require further investigation into its calculation or a special dividend event. JNJ (<strong>2.53%</strong>) and MRK (<strong>3.32%</strong>) also provide solid yields. This peer comparison underscores BMY's strong ROE and attractive dividend yield but also highlights areas like revenue growth and net margin where it lags behind some of its larger, more dynamic competitors.</p>
<h2>BMY Insider Transactions: Recent Activity &amp; Ownership Changes</h2>
<p>Insider transactions can offer a glimpse into how a company‚Äôs own executives and directors perceive its future prospects. Over the last three months, Bristol-Myers Squibb has seen a total of <strong>19</strong> insider transactions. It‚Äôs important to note that a significant portion of these ‚Äî <strong>10</strong> to be exact ‚Äî were related to stock awards or tax-related dispositions, rather than discretionary market buys or sells. Additionally, there were <strong>8</strong> option exercises, which could indicate either confidence in future price appreciation or simply routine portfolio management activities.</p>
<p>Unfortunately, detailed valuation analysis for these transactions is somewhat limited, as price data was only available for <strong>32%</strong> of the transactions, with estimates used where possible. Despite this, the patterns in share volume remain informative. This mixed activity, predominantly compensation-related rather than direct market moves, is quite typical for established companies. Insiders often balance their personal financial planning with maintaining confidence in the fundamental health of the business.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Insider Name</th>
<th>Type</th>
<th>Shares Changed</th>
<th>Price</th>
<th>Shares After</th>
<th>Transaction Date</th>
<th>Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shanahan Karin</td>
<td>SELL (Tax Payment) [F]</td>
<td>-3,213</td>
<td>$46.07</td>
<td>16,865</td>
<td>2025-11-01</td>
<td>2025-11-04</td>
</tr>
<tr>
<td>Meyers Gregory Scott</td>
<td>SELL (Tax Payment) [F]</td>
<td>-2,665</td>
<td>$46.07</td>
<td>19,718</td>
<td>2025-11-01</td>
<td>2025-11-04</td>
</tr>
<tr>
<td>BOERNER CHRISTOPHER S.</td>
<td>SELL (Tax Payment) [F]</td>
<td>-1,238</td>
<td>$46.07</td>
<td>1,182</td>
<td>2025-11-01</td>
<td>2025-11-04</td>
</tr>
<tr>
<td>Gallman Cari</td>
<td>SELL (Exercise) [M]</td>
<td>-4,558</td>
<td>~$45.11<em></em></td>
<td>4,559</td>
<td>2025-10-02</td>
<td>2025-10-06</td>
</tr>
<tr>
<td>Gallman Cari</td>
<td>SELL (Tax Payment) [F]</td>
<td>-2,332</td>
<td>$45.73</td>
<td>11,066</td>
<td>2025-10-02</td>
<td>2025-10-06</td>
</tr>
<tr>
<td>Gallman Cari</td>
<td>BUY (Exercise) [M]</td>
<td>+4,558</td>
<td>~$45.11</td>
<td>13,398</td>
<td>2025-10-02</td>
<td>2025-10-06</td>
</tr>
</tbody>
</table>
<h2>Key Risk Factors for Investing in BMY Stock</h2>
<p>Before considering any investment in Bristol-Myers Squibb (BMY), it's crucial for potential investors to be fully aware of the inherent risks. While every stock carries some level of risk, certain factors are particularly relevant to BMY based on current data and market dynamics. This list highlights key considerations, but remember, it may not encompass every possible risk.</p>
<ul>
<li>‚ö†Ô∏è <strong>Overbought Conditions (RSI):</strong> The Relative Strength Index (RSI) for BMY is currently high at <strong>86.1</strong>. An RSI above 70 typically suggests that the stock is overbought, indicating that a potential pullback or period of consolidation could be imminent. Chasing a stock in overbought territory carries increased short-term risk.</li>
<li>‚ö†Ô∏è <strong>Significant Financial Leverage:</strong> BMY carries a high Debt-to-Equity ratio of <strong>2.74x</strong>. This substantial financial leverage means the company relies heavily on debt to fund its operations and growth. While this can amplify returns in good times, it also significantly increases financial risk, especially if interest rates rise or the company faces cash flow challenges.</li>
<li>‚ö†Ô∏è <strong>General Market Fluctuations:</strong> Like all stocks, BMY is susceptible to broader market fluctuations and general economic conditions. The Healthcare sector, while often seen as defensive, is not immune to economic downturns, regulatory changes, or shifts in investor sentiment that can impact stock prices.</li>
</ul>
<p>Carefully weigh these risk factors against your personal investment goals and risk tolerance. Diligence is key in navigating the pharmaceutical market.</p>
<h2>BMY Analyst Insights &amp; Wall Street Consensus: Price Targets</h2>
<p>What do Wall Street analysts think about Bristol-Myers Squibb (BMY) right now? The consensus view among analysts is a <strong>'Hold'</strong> recommendation. This consensus is derived from the insights of <strong>22</strong> analysts who contributed to this outlook, offering a balanced perspective on the stock's potential.</p>
<p>When it comes to price targets, the average target set by these analysts is <strong>$53.05</strong>. This target falls within a broad range, with a high target price of <strong>$68.00</strong> and a low target price of <strong>$36.00</strong>. The average target of <strong>$53.05</strong> suggests a potential upside of approximately <strong>4.1%</strong> compared to the current price of <strong>$50.96</strong>.</p>
<table class="financial-data-table">
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>Hold</td>
</tr>
<tr>
<td><strong>Mean Target Price</strong></td>
<td>$53.05</td>
</tr>
<tr>
<td><strong>High Target Price</strong></td>
<td>$68.00</td>
</tr>
<tr>
<td><strong>Low Target Price</strong></td>
<td>$36.00</td>
</tr>
<tr>
<td><strong>Number of Analyst Opinions</strong></td>
<td>22</td>
</tr>
</tbody>
</table>
<p>This "Hold" consensus and the modest upside potential reflect the overall sentiment among analysts regarding BMY's near-to-medium term outlook. It typically means that analysts believe the stock is fairly valued at its current price, and while it might offer some upside, it's not expected to see explosive growth or a significant downturn based on current information. Investors should use this consensus as one data point among many, understanding that individual analyst opinions can vary widely within this range.</p>
<h2>Latest News &amp; Developments Impacting Bristol-Myers Squibb (BMY)</h2>
<p>Staying current with the latest news and developments is paramount for any investor, as recent events can significantly impact a stock's trajectory. Here are some of the key headlines that have emerged in the last few days, offering insights into potential catalysts affecting Bristol-Myers Squibb (BMY):</p>
<ul>
<li><strong>Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock</strong><br/><em>Publisher: Investor's Business Daily, Published: 2025-12-03T21:10:43Z</em><br/>This article indicates that an unexpected delay for BMY's drug, Cobenfy, has generated a positive market reaction, which can sometimes occur if a delay is perceived to reduce near-term R&amp;D costs or realign expectations positively.</li>
<li><strong>Sector Update: Health Care Stocks Higher Late Afternoon</strong><br/><em>Publisher: MT Newswires, Published: 2025-12-03T20:50:23Z</em><br/>This broader sector news suggests a positive sentiment across the healthcare industry, which would naturally provide tailwinds for BMY, a major player in the space.</li>
<li><strong>Sector Update: Health Care Stocks Higher Wednesday Afternoon</strong><br/><em>Publisher: MT Newswires, Published: 2025-12-03T18:35:53Z</em><br/>Similar to the above, this further reinforces the positive momentum observed in the healthcare sector, contributing to a favorable trading environment for BMY.</li>
<li><strong>Bristol-Myers Stock Rises on Alzheimer‚Äôs Drug Study Update</strong><br/><em>Publisher: The Wall Street Journal, Published: 2025-12-03T18:12:52Z</em><br/>This is a significant catalyst, as positive news regarding a study update for an Alzheimer's drug can greatly impact a pharmaceutical company's prospects, given the vast market potential for such treatments. You can always check <a href="https://www.marketwatch.com/investing/stock/bmy" rel="noopener" target="_blank">MarketWatch for similar updates</a>.</li>
<li><strong>Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?</strong><br/><em>Publisher: Zacks, Published: 2025-12-03T16:30:16Z</em><br/>While this news item focuses on a peer, Sarepta Therapeutics, its strong performance can sometimes indicate broader positive trends or investor confidence within specific sub-sectors of the drug manufacturing industry, which could indirectly benefit BMY.</li>
</ul>
<p>These recent developments from December 3, 2025, highlight the dynamic nature of the pharmaceutical market and offer specific reasons for BMY's recent movements and the general positive sentiment in the healthcare sector.</p>
<h2>BMY Stock Conclusion &amp; Investment Outlook</h2>
<p>Bringing all the pieces of our Bristol-Myers Squibb (BMY) analysis together, we can form a comprehensive picture for investors. The stock presents a fascinating blend of strong technical momentum and nuanced fundamental performance.</p>
<h3>Short-Term Technical Snapshot</h3>
<ul>
<li>‚ñ≤ <strong>Overall Technical Sentiment:</strong> Currently, the technical picture for BMY is <strong>Bullish</strong>.</li>
<li>‚ñ≤ <strong>Price Trend vs MAs:</strong> The price trend is bullish, trading comfortably above both its 50-day and 200-day Simple Moving Averages.</li>
<li>‚ö†Ô∏è <strong>Momentum (RSI):</strong> A significant caution flag is the Relative Strength Index (RSI) at <strong>86.1</strong>, indicating overbought conditions, which could signal a short-term pullback.</li>
<li>üìä <strong>Support / Resistance (30d):</strong> Key trading levels to watch are approximately <strong>~$45.27</strong> for support and <strong>~$51.34</strong> for resistance.</li>
</ul>
<h3>Longer-Term Fundamental &amp; Forecast Outlook</h3>
<ul>
<li>‚ñº <strong>1-Year Avg. Forecast:</strong> The model-based 1-year average forecast suggests a relatively flat outlook with about a <strong>-2.8%</strong> average change, targeting approximately <strong>‚âà$49.54</strong>.</li>
<li>‚óè <strong>Fundamental Health:</strong> The assessment of fundamental health is nuanced, with an impressive ROE of <strong>33.78%</strong> balanced against a high Debt/Equity ratio of <strong>2.74x</strong>.</li>
<li>‚ûï <strong>Valuation Snapshot:</strong> From a valuation perspective, BMY appears <strong>Potentially Attractive</strong>, especially with a Forward P/E of <strong>7.25x</strong>.</li>
<li>‚óè <strong>Recent Growth (YoY):</strong> The company shows moderate growth, with revenue up <strong>2.80%</strong> and earnings growth surging by <strong>80.90%</strong> year-over-year.</li>
<li>‚óè <strong>Analyst Consensus:</strong> Wall Street analysts currently hold a <strong>'Hold'</strong> consensus, with a mean target price of <strong>$53.05</strong>.</li>
</ul>
<h3>Overall Assessment &amp; Outlook</h3>
<p>Synthesizing all this data, BMY currently exhibits strong bullish technicals, yet these are coupled with fundamentals that suggest caution in certain areas. From a valuation standpoint, it looks potentially attractive, particularly given its forward earnings multiple. However, the one-year forecast implies a relatively flat performance, with an average target near <strong>‚âà$49.54</strong>.</p>
<p>For investors, this means a careful consideration of these points relative to the potential risks outlined earlier, such as the high debt load and overbought technical conditions. Your investment decisions should always align with your strategic goals and risk tolerance. While BMY has shown strong operational performance and dividend appeal, prudent investors will weigh the current momentum against potential headwinds and the longer-term outlook.</p>
<h2>Frequently Asked Questions About BMY Stock</h2>
<h3>What is the BMY stock price prediction for the next year (2025-2026)?</h3>
<p>Based on current models, the average 1-year price forecast for BMY is approximately <strong>$49.54</strong>. This represents a potential <strong>-2.8%</strong> change from the recent price of <strong>$50.96</strong>. It's crucial to remember that this is a model-driven estimate, not a guarantee, and actual prices will fluctuate based on numerous market factors and company developments.</p>
<h3>Will BMY stock go up or down?</h3>
<p>The 1-year forecast model suggests the price might see modest losses on average (<strong>-2.8%</strong> potential). However, the short-term direction is highly uncertain and heavily influenced by prevailing market sentiment (currently 'Bullish'), breaking news, and overall economic conditions. Technical indicators, such as the overbought RSI, also provide clues for near-term direction, suggesting potential for a pullback before any sustained upward movement.</p>
<h3>Is BMY stock a good investment right now?</h3>
<p>Whether BMY is a 'good buy' now involves balancing various elements. Technically, the RSI indicates overbought conditions (RSI: <strong>86.1</strong>), suggesting caution or potential for a pullback. Fundamentally, the company shows strong profitability and cash flow but also carries a high Debt/Equity ratio (<strong>2.74x</strong>). You should weigh the company's valuation, stability, growth prospects, and the 3 potentially significant risk factors specific to BMY (see Risk Factors section) against your own investment goals and risk profile. This report is informational; consulting a financial advisor before investing is always recommended.</p>
<h3>How volatile is BMY stock?</h3>
<p>Based on the recent 30-day price action, BMY's annualized volatility is approximately <strong>28.4%</strong>. This level is currently considered moderate, indicating the degree of recent price fluctuation. This aligns with its Beta of <strong>0.31x</strong>, suggesting it's less volatile than the broader market. Higher volatility means larger potential price swings, both up and down.</p>
<h3>What is BMY's P/E ratio and what does it mean?</h3>
<p>BMY's Trailing P/E ratio (based on past earnings) is <strong>17.16x</strong>, which is considered moderate. The Forward P/E (based on expected earnings) is <strong>7.25x</strong>, suggesting anticipated earnings growth. A P/E ratio indicates how much investors are paying per dollar of earnings. You should compare this to industry peers and historical levels to gauge its relative valuation. A high P/E isn't necessarily bad if strong growth justifies it (you can check the PEG ratio in the Valuation Metrics section for a more complete picture).</p>
<h3>What are the key upcoming events for BMY?</h3>
<p>A key upcoming event for income investors is the ex-dividend date on <strong>2025-10-03</strong>. Beyond this, analysts should monitor broader macroeconomic shifts, competitive actions within the pharmaceutical industry, and any major corporate announcements regarding drug development, clinical trials, or mergers and acquisitions.</p>
<h3>What does BMY's liquidity position reveal about its financial health?</h3>
<p>BMY's financial health includes an adequate Current Ratio of <strong>1.27x</strong>, suggesting it can cover its short-term obligations. However, its robust operating cash flow of <strong>$16.62 billion</strong> and levered free cash flow of <strong>$14.72 billion</strong> provide a significant buffer. These strong cash flow figures are critical factors in its ability to fund operations, service its substantial debt, and invest in future growth.</p>
<h2>Important Report Information &amp; Disclaimer</h2>
<p><strong>Report Generated On:</strong> 2025-12-04 10:19:09 UTC</p>
<p><strong>Current Date Context:</strong> 2025-12-04</p>
<p><strong>Data Primarily Sourced From:</strong> Yahoo Finance API (via yfinance), potentially supplemented by FRED Economic Data.</p>
<p><strong>Important Caveats:</strong> Financial data may have reporting lags. Technical indicators are inherently backward-looking. Forecasts are probabilistic model outputs, not certainties, and subject to significant error ranges and changing assumptions.</p>
<p><strong>ESSENTIAL DISCLAIMER:</strong> This report is automatically generated for informational and educational purposes ONLY. It does NOT constitute financial, investment, trading, legal, or tax advice, nor should it be interpreted as a recommendation or solicitation to buy, sell, hold, or otherwise transact in any security mentioned.</p>
<p>All investments carry risk, including the potential loss of principal. Past performance is not indicative or predictive of future results. Market conditions are dynamic and can change rapidly. Financial models and data sources may contain errors or inaccuracies.</p>
<p>Readers are strongly urged to conduct their own thorough and independent due diligence. Consult with one or more qualified, licensed financial professionals, investment advisors, and/or tax advisors before making any investment decisions. Understand your own risk tolerance, financial situation, and investment objectives.</p>
<p>The creators, generators, and distributors of this report assume NO liability whatsoever for any actions taken, decisions made, or interpretations drawn based on the information provided herein. Use this information entirely at your own risk.</p>

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What is the BMY stock price prediction for the next year (2025-2026)?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Based on current models, the average 1-year price forecast for BMY is approximately $49.54. This represents a potential -2.8% change from the recent price of $50.96. It's crucial to remember that this is a model-driven estimate, not a guarantee, and actual prices will fluctuate based on numerous market factors and company developments."
      }
    },
    {
      "@type": "Question",
      "name": "Will BMY stock go up or down?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The 1-year forecast model suggests the price might see modest losses on average (-2.8% potential). However, the short-term direction is highly uncertain and heavily influenced by prevailing market sentiment (currently 'Bullish'), breaking news, and overall economic conditions. Technical indicators, such as the overbought RSI, also provide clues for near-term direction, suggesting potential for a pullback before any sustained upward movement."
      }
    },
    {
      "@type": "Question",
      "name": "Is BMY stock a good investment right now?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Whether BMY is a 'good buy' now involves balancing various elements. Technically, the RSI indicates overbought conditions (RSI: 86.1), suggesting caution or potential for a pullback. Fundamentally, the company shows strong profitability and cash flow but also carries a high Debt/Equity ratio (2.74x). You should weigh the company's valuation, stability, growth prospects, and the 3 potentially significant risk factors specific to BMY (see Risk Factors section) against your own investment goals and risk profile. This report is informational; consulting a financial advisor before investing is always recommended."
      }
    },
    {
      "@type": "Question",
      "name": "How volatile is BMY stock?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Based on the recent 30-day price action, BMY's annualized volatility is approximately 28.4%. This level is currently considered moderate, indicating the degree of recent price fluctuation. This aligns with its Beta of 0.31x, suggesting it's less volatile than the broader market. Higher volatility means larger potential price swings, both up and down."
      }
    },
    {
      "@type": "Question",
      "name": "What is BMY's P/E ratio and what does it mean?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "BMY's Trailing P/E ratio (based on past earnings) is 17.16x, which is considered moderate. The Forward P/E (based on expected earnings) is 7.25x, suggesting anticipated earnings growth. A P/E ratio indicates how much investors are paying per dollar of earnings. You should compare this to industry peers and historical levels to gauge its relative valuation. A high P/E isn't necessarily bad if strong growth justifies it (you can check the PEG ratio in the Valuation Metrics section for a more complete picture)."
      }
    },
    {
      "@type": "Question",
      "name": "What are the key upcoming events for BMY?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "A key upcoming event for income investors is the ex-dividend date on 2025-10-03. Beyond this, analysts should monitor broader macroeconomic shifts, competitive actions within the pharmaceutical industry, and any major corporate announcements regarding drug development, clinical trials, or mergers and acquisitions."
      }
    },
    {
      "@type": "Question",
      "name": "What does BMY's liquidity position reveal about its financial health?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "BMY's financial health includes an adequate Current Ratio of 1.27x, suggesting it can cover its short-term obligations. However, its robust operating cash flow of $16.62 billion and levered free cash flow of $14.72 billion provide a significant buffer. These strong cash flow figures are critical factors in its ability to fund operations, service its substantial debt, and invest in future growth."
      }
    }
  ]
}
</script>

    
</body>
</html>
